REGN

Regeneron Pharmaceuticals, Inc. - Q1 2010 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended March 31, 2010. Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products. Its only currently marketed product is ARCALYST® (rilonacept) for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). The company maintains significant strategic collaborations with sanofi-aventis (antibody discovery and aflibercept) and Bayer HealthCare (VEGF Trap-Eye).

Key Financial Metrics

Note: Q1 2009 figures have been revised due to accounting changes regarding facility lease obligations (see Material Changes).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 38% to $103.5 million, driven primarily by higher collaboration revenue from sanofi-aventis ($68.7M vs $49.7M) and Bayer HealthCare ($13.1M vs $10.0M). Net product sales for ARCALYST increased to $9.9 million (including $4.8M of previously deferred revenue recognized due to improved historical data on returns/rebates).
• Expense Increase: Operating expenses rose to $132.2 million from $92.1 million. R&D expenses increased 46% to $117.5 million, attributed to higher clinical trial costs (VEGF Trap-Eye, rilonacept), increased headcount (1,087 vs 938), and expanded manufacturing activities.
• Widened Net Loss: Net loss doubled to $30.5 million due to the significant increase in R&D spending outpacing revenue growth.
• Accounting Revisions: The company revised Q1 2009 financial statements to capitalize landlord construction costs for Tarrytown facilities as a non-cash transaction, offset by a facility lease obligation. This reduced the reported Q1 2009 net loss from $17.5M to $15.4M.

Guidance, Outlook, and Risks

• Clinical Milestones:
  • Rilonacept: Phase 3 trials for gout (PRE-SURGE 1, SURGE) are fully enrolled; data expected in Q2 2010.
  • VEGF Trap-Eye: Positive Phase 2 results reported for Diabetic Macular Edema (DME). Phase 3 trials for wet AMD (VIEW 1 & 2) are fully enrolled with data expected in late 2010.
  • Aflibercept: Phase 3 trials in oncology (colorectal, lung, prostate cancer) are fully enrolled. Interim analysis for colorectal cancer expected in H2 2010.
• Liquidity: The company holds approximately $413.5 million in cash, cash equivalents, and marketable securities. Management believes existing resources, including collaboration funding, will meet operating needs through at least 2012.
• Capital Expenditures: Expected to be $60-$90 million for the remainder of 2010, primarily for expanding Rensselaer manufacturing facilities and Tarrytown tenant improvements.
• Risks: Key risks include the uncertainty of clinical trial outcomes, potential termination of collaborations with sanofi-aventis or Bayer, patent infringement litigation (specifically regarding VEGF inhibitors and IL-6 antibodies), and the need for additional financing if product development costs exceed projections.

Investor Verification Checklist

• Collaboration Dependency: Verify the stability and funding terms of the sanofi-aventis antibody collaboration, which funds a significant portion of R&D.
• Clinical Trial Timelines: Monitor the Q2 2010 data readouts for rilonacept (gout) and late 2010 data for VEGF Trap-Eye (wet AMD) as critical value drivers.
• Revenue Recognition: Confirm the sustainability of ARCALYST revenue growth now that deferred revenue recognition has stabilized.
• Capital Burn Rate: Assess whether the $10M quarterly operating cash burn is sustainable given the projected $60-$90M capital expenditure plan for the rest of 2010.
• Patent Landscape: Review ongoing or potential litigation risks regarding Genentech and Roche patents related to VEGF and IL-6 technologies.